DurgicalDurgical
EN
Open the app

Other glucose-lowering drugs !

Smaller groups for type 2 (and type 1) diabetes: drugs that slow carbohydrate digestion, short-acting insulin secretagogues and an amylin analogue.

Updated 2026-11-01

What they are

Alpha-glucosidase inhibitors (acarbose), meglitinides (repaglinide) and amylin analogues (pramlintide). Each targets mainly the glucose rise after meals.

Mechanism of action

Acarbose blocks the brush-border alpha-glucosidases that split starch and sucrose, so carbohydrate is absorbed later and more slowly. Repaglinide closes the beta-cell KATP channel like a sulfonylurea but at a different site of SUR1, with a quick, short action around meals. Pramlintide copies amylin, a beta-cell hormone that slows gastric emptying, reduces glucagon after meals and increases fullness.

Target: Intestinal alpha-glucosidases, SUR1 of the KATP channel, amylin receptors

Drugs in this class

Others in the class

  • miglitol (alpha-glucosidase inhibitor)
  • nateglinide (meglitinide)
  • voglibose

Test yourself

Think of the answer, then tap the question to see it.

Why is table sugar a poor treatment for hypoglycemia in a patient on acarbose?

Sucrose must be split by intestinal alpha-glucosidases before absorption, and acarbose blocks them; glucose is absorbed directly.

How does repaglinide differ from a sulfonylurea?

Both close the beta-cell KATP channel, but repaglinide is not a sulfonylurea, binds a different site and acts quickly and briefly, so it is given with meals.

Which hormone does pramlintide copy, and which cell normally makes it?

Amylin, released by the pancreatic beta cell together with insulin.

Add to my cards (3)

← All of pharmacology

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: DailyMed - ACARBOSE tablet (DailyMed (U.S. National Library of Medicine), 2026); DailyMed - REPAGLINIDE tablet (DailyMed (U.S. National Library of Medicine), 2026); Pramlintide Injection: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.